Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bucindolol - ARCA biopharma

Drug Profile

Bucindolol - ARCA biopharma

Alternative Names: BMY 13105; Bucindolol hydrochloride; Gencaro; MJ 13105; MJ 131051

Latest Information Update: 27 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer ARCA biopharma Inc; Medtronic
  • Class Antiarrhythmics; Heart failure therapies; Propanolamines; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Beta 2 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Atrial fibrillation
  • Discontinued Heart failure; Myocardial infarction

Most Recent Events

  • 20 Dec 2018 ARCA biopharma Inc submits amended Special Protocol Assessment (SPA) request to US FDA for its planned phase III PRECISION-AF trial in Atrial fibrillation (Prevention, Recurrent)
  • 11 Nov 2018 Efficacy data from a phase II GENETIC-AF trial presented at the at the 91st Annual Scientific Sessions of the American Heart Association (AHA-2018)
  • 18 Sep 2018 ARCA Biopharma anticipates to initiate the phase III PRECISION-AF trial for Atrial fibrillation (Prevention, Recurrent) in the second half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top